This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (221)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Randomized Controlled Trial  • Alert me on articles by topic

Salim Yusuf, DPhil,FRCPC; Hertzel Gerstein, FRCP; Byron Hoogwerf, MD; Janice Pogue, MSc; Jackie Bosch, MSc; Bruce H. R. Wolffenbuttel, MD; Bernard Zinman, FRCP; for the HOPE Study Investigators

JAMA. 2001;286:1882-1885.

Context  Type 2 diabetes is a growing clinical and public health problem. Preventive efforts related to lifestyle modification are not always successful; therefore, alternative prevention strategies need to be studied.

Objective  To investigate the effectiveness of ramipril, an angiotensin-converting enzyme inhibitor, in preventing diabetes among high-risk persons.

Design, Setting, and Participants  The randomized, controlled Heart Outcomes Prevention Evaluation trial of 5720 patients older than 55 years without known diabetes but with vascular disease who were followed up for a mean of 4.5 years. The study included 267 hospitals in 19 countries and was conducted between 1994 and 1999.

Intervention  Patients were randomly assigned to receive ramipril, up to 10 mg/d (n = 2837), or placebo (n = 2883).

Main Outcome Measure  Diagnosis of diabetes determined from self-report at follow-up visits every 6 months, compared between the 2 groups.

Results  One hundred and two individuals (3.6%) in the ramipril group developed diabetes compared with 155 (5.4%) in the placebo group (relative risk [RR], 0.66; 95% confidence interval [CI], 0.51-0.85, P<.001). Similar results were noted when different diagnostic criteria were used; in the ramipril group, the RR for diagnosis of diabetes and hemoglobin A_1c greater than 110% was 0.60 (95% CI, 0.43-0.85), for initiation of glucose-lowering therapy, 0.56 (95% CI, 0.41-0.77), and for both, 0.51 (95% CI, 0.34-0.76). These effects were also consistently seen in several subgroups examined.

Conclusions  Ramipril is associated with lower rates of new diagnosis of diabetes in high-risk individuals. Because these results have important clinical and public health implications, this hypothesis requires prospective confirmation.

Author Affiliations: McMaster University, Hamilton, Canada (Drs Yusuf and Gerstein and Mss Pogue and Bosch); Cleveland Clinic Foundation, Cleveland, Ohio (Dr Hoogwerf); Clinic of Maastricht, Maastricht, the Netherlands (Dr Wolffenbuttel); Mt Sinai and Toronto Hospitals, Toronto, Canada (Dr Zinman). A complete list of the HOPE investigators has been previously published.¹¹

RELATED ARTICLE

October 17, 2001
JAMA. 2001;286(15):1911-1912.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf et al.
NEJM 2008;0:NEJMoa0804593v1-1.
ABSTRACT | FULL TEXT  

Lewis K. Dahl Memorial Lecture: The Renin-Angiotensin System and Aging
Diz
Hypertension 2008;52:37-43.
FULL TEXT  

Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors
Solski and Longyhore
Am J Health Syst Pharm 2008;65:935-940.
ABSTRACT | FULL TEXT  

Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Black et al.
Diabetes Care 2008;31:353-360.
ABSTRACT | FULL TEXT  

Type 2 diabetes in people of South Asian origin: potential strategies for prevention
Chowdhury and Hitman
British Journal of Diabetes & Vascular Disease 2007;7:279-282.
ABSTRACT  

In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
Okin et al.
Hypertension 2007;50:984-990.
ABSTRACT | FULL TEXT  

Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy
Jin and Pan
Nephrol Dial Transplant 2007;22:1943-1949.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Trials That Matter: Rosiglitazone, Ramipril, and the Prevention of Type 2 Diabetes
Nathan and Berkwits
ANN INTERN MED 2007;146:461-463.
FULL TEXT  

The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients
Negro and Hassan
Journal of Renin-Angiotensin-Aldosterone System 2006;7:243-246.
ABSTRACT  

Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes
Fonseca and Kahn
J. Clin. Endocrinol. Metab. 2006;91:4762-4763.
FULL TEXT  

Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Barzilay et al.
Arch Intern Med 2006;166:2191-2201.
ABSTRACT | FULL TEXT  

Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation
Pfeffer and Frohlich
Am. J. Physiol. Heart Circ. Physiol. 2006;291:H2021-H2025.
ABSTRACT | FULL TEXT  

Loss of Nocturnal Blood Pressure Fall in Patients With Renal Impairment--Reply
Davidson and Brotman
Arch Intern Med 2006;166:2159-2159.
FULL TEXT  

Effect of Ramipril on the Incidence of Diabetes
The DREAM Trial Investigators
NEJM 2006;355:1551-1562.
ABSTRACT | FULL TEXT  

Reciprocal Relationships Between Insulin Resistance and Endothelial Dysfunction: Molecular and Pathophysiological Mechanisms
Kim et al.
Circulation 2006;113:1888-1904.
ABSTRACT | FULL TEXT  

Signaling by the Angiotensin-Converting Enzyme
Fleming
Circ. Res. 2006;98:887-896.
ABSTRACT | FULL TEXT  

Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
Thornley-Brown et al.
Arch Intern Med 2006;166:797-805.
ABSTRACT | FULL TEXT  

Quinapril Treatment Increases Insulin-Stimulated Endothelial Function and Adiponectin Gene Expression in Patients with Type 2 Diabetes
Hermann et al.
J. Clin. Endocrinol. Metab. 2006;91:1001-1008.
ABSTRACT | FULL TEXT  

Hemostatic Markers of Endothelial Dysfunction and Risk of Incident Type 2 Diabetes: The Framingham Offspring Study
Meigs et al.
Diabetes 2006;55:530-537.
ABSTRACT | FULL TEXT  

Elevated Markers of Endothelial Dysfunction Predict Type 2 Diabetes Mellitus in Middle-Aged Men and Women From the General Population
Thorand et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:398-405.
ABSTRACT | FULL TEXT  

Prevention of Progression in Diabetic Nephropathy
Hall
Diabetes Spectr. 2006;19:18-24.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes-2006
American Diabetes Association
Diabetes Care 2006;29:S4-S42.
FULL TEXT  

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients
Tenenbaum et al.
Eur Heart J 2005;26:2032-2038.
ABSTRACT | FULL TEXT  

The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes
Gillespie et al.
Diabetes Care 2005;28:2261-2266.
ABSTRACT | FULL TEXT  

A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combination Versus Amlodipine in Black Hypertensives
Weir et al.
Hypertension 2005;46:508-513.
ABSTRACT | FULL TEXT  

Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes: Results of the HOPE Study Extension
HOPE/HOPE-TOO Study Investigators
Circulation 2005;112:1339-1346.
ABSTRACT | FULL TEXT  

Second World Congress on the Insulin Resistance Syndrome: Hypertension, cardiovascular disease, and treatment approaches
Bloomgarden
Diabetes Care 2005;28:2073-2080.
FULL TEXT  

Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure
Yusuf et al.
Circulation 2005;112:48-53.
ABSTRACT | FULL TEXT  

Effects of Short-Term Glucocorticoids on Cardiovascular Biomarkers
Brotman et al.
J. Clin. Endocrinol. Metab. 2005;90:3202-3208.
ABSTRACT | FULL TEXT  

Management of Heart Failure Patients with Preserved Left Ventricular Ejection Fraction
Cohen-Solal
Journal of Renin-Angiotensin-Aldosterone System 2005;6:S15-S16.
ABSTRACT  

Retinal Arteriolar Narrowing, Hypertension, and Subsequent Risk of Diabetes Mellitus
Wong et al.
Arch Intern Med 2005;165:1060-1065.
ABSTRACT | FULL TEXT  

Deletion of the Angiotensin Type 2 Receptor (AT2R) Reduces Adipose Cell Size and Protects From Diet-Induced Obesity and Insulin Resistance
Yvan-Charvet et al.
Diabetes 2005;54:991-999.
ABSTRACT | FULL TEXT  

Hypertension Genes Are Genetic Markers for Insulin Sensitivity and Resistance
Guo et al.
Hypertension 2005;45:799-803.
ABSTRACT | FULL TEXT  

A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes
Padwal et al.
Diabetes Care 2005;28:736-744.
ABSTRACT | FULL TEXT  

Preventing Type 2 Diabetes Mellitus
Curtis and Wilson
J Am Board Fam Med 2005;18:37-43.
ABSTRACT | FULL TEXT  

Standards of Medical Care in Diabetes
American Diabetes Association
Diabetes Care 2005;28:S4-S36.
FULL TEXT  

New aspects in the pathogenesis of diabetic atherothrombosis
Moreno and Fuster
J Am Coll Cardiol 2004;44:2293-2300.
ABSTRACT | FULL TEXT  

Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease
The PEACE Trial Investigators
NEJM 2004;351:2058-2068.
ABSTRACT | FULL TEXT  

Effects of Glycemic Control on Diabetes Complications and on the Prevention of Diabetes
Skyler
Clin. Diabetes 2004;22:162-166.
ABSTRACT | FULL TEXT  

Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome
Prasad and Quyyumi
Circulation 2004;110:1507-1512.
FULL TEXT  

Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart
Lim et al.
Arch Intern Med 2004;164:1737-1748.
ABSTRACT | FULL TEXT  

Metabolic and Inflammation Variable Clusters and Prediction of Type 2 Diabetes: Factor Analysis Using Directly Measured Insulin Sensitivity
Hanley et al.
Diabetes 2004;53:1773-1781.
ABSTRACT | FULL TEXT  

Peroxisome Proliferator-Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease
Tenenbaum et al.
Circulation 2004;109:2197-2202.
ABSTRACT | FULL TEXT  

Is Oxidative Stress the Pathogenic Mechanism Underlying Insulin Resistance, Diabetes, and Cardiovascular Disease? The Common Soil Hypothesis Revisited
Ceriello and Motz
Arterioscler. Thromb. Vasc. Bio. 2004;24:816-823.
ABSTRACT | FULL TEXT  

Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR{gamma}-Modulating Activity
Benson et al.
Hypertension 2004;43:993-1002.
ABSTRACT | FULL TEXT  

Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus
Meigs et al.
JAMA 2004;291:1978-1986.
ABSTRACT | FULL TEXT  

Preventing Type II Diabetes Mellitus
Prisant
J Clin Pharmacol 2004;44:406-413.
ABSTRACT | FULL TEXT  

Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women
Hu et al.
Diabetes 2004;53:693-700.
ABSTRACT | FULL TEXT  

The Metabolic Syndrome and Aging
Morley
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M139-142.
FULL TEXT  

Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
Ma et al.
Diabetes 2004;53:336-346.
ABSTRACT | FULL TEXT  

Antihypertensive Therapy and Incidence of Type 2 Diabetes: A systematic review
Padwal and Laupacis
Diabetes Care 2004;27:247-255.
ABSTRACT | FULL TEXT  

Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management
Hurst and Lee
ANN INTERN MED 2003;139:824-834.
ABSTRACT | FULL TEXT  

Is Type 2 Diabetes Mellitus a Vascular Condition?
Hu and Stampfer
Arterioscler. Thromb. Vasc. Bio. 2003;23:1715-1716.
FULL TEXT  

The Endocrine Society Meeting: Topics in Insulin Sensitivity and Hypertension
Bloomgarden
Diabetes Care 2003;26:2679-2688.
FULL TEXT  

Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies
Meigs et al.
Diabetes 2003;52:2160-2167.
ABSTRACT | FULL TEXT  

Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension
Furuhashi et al.
Hypertension 2003;42:76-81.
ABSTRACT | FULL TEXT  

Minireview: Adiposity, Inflammation, and Atherogenesis
Lyon et al.
Endocrinology 2003;144:2195-2200.
ABSTRACT | FULL TEXT  

HOPE Study Impact on ACE Inhibitors Use
Hemels et al.
The Annals of Pharmacotherapy 2003;37:640-645.
ABSTRACT | FULL TEXT  

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors
Messerli and Weber
JAMA 2003;289:2067-2068.
FULL TEXT  

Vasopeptidase Inhibitor Omapatrilat Induces Profound Insulin Sensitization and Increases Myocardial Glucose Uptake in Zucker Fatty Rats: Studies Comparing a Vasopeptidase Inhibitor, Angiotensin-Converting Enzyme Inhibitor, and Angiotensin II Type I Receptor Blocker
Wang et al.
Circulation 2003;107:1923-1929.
ABSTRACT | FULL TEXT  

The Daily Walk or the Daily Pill?
Marks
Clin. Diabetes 2003;21:51-52.
FULL TEXT  

Applying the Lessons of the DPP to Clinical Practice
Inzucchi and Sherwin
Clin. Diabetes 2003;21:91-92.
FULL TEXT  

American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25-26 August 2002, Washington, DC
Bloomgarden
Diabetes Care 2003;26:1297-1303.
FULL TEXT  

Insulin resistance: a global epidemic in need of effective therapies
Califf
Eur Heart J Suppl 2003;5:C13-C18.
ABSTRACT  

Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure: Insight From the Studies Of Left Ventricular Dysfunction (SOLVD)
Vermes et al.
Circulation 2003;107:1291-1296.
ABSTRACT | FULL TEXT  

Pharmacological Agents That Directly Modulate Insulin Secretion
Doyle and Egan
Pharmacol. Rev. 2003;55:105-131.
ABSTRACT | FULL TEXT  

Pharmacologic Treatment of Type 2 Diabetes
Bloomgarden
Diabetes Care 2003;26:526-533.
FULL TEXT  

Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines
Mooradian
Arch Intern Med 2003;163:33-40.
ABSTRACT | FULL TEXT  

Pharmacologic Approaches to the Prevention of Type 2 Diabetes in High Risk Pediatric Patients
Freemark
J. Clin. Endocrinol. Metab. 2003;88:3-13.
FULL TEXT  

Functional Interplay Between Angiotensin II and Nitric Oxide: Cyclic GMP as a Key Mediator
Yan et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:26-36.
ABSTRACT | FULL TEXT  

Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance?
Defronzo
British Journal of Diabetes & Vascular Disease 2003;3:S24-S40.
ABSTRACT  

Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies
Lonn et al.
Eur Heart J Suppl 2003;5:A43-A48.
ABSTRACT  

Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells
Sharma et al.
Hypertension 2002;40:609-611.
ABSTRACT | FULL TEXT  

Type 2 diabetes and atherosclerotic cardiovascular disease: do they share common antecedents?
Krentz
British Journal of Diabetes & Vascular Disease 2002;2:370-378.
ABSTRACT  

Prevention of diabetes in cardiovascular studies: implications for the aetiology of type 2 diabetes
Mcdougall and Fisher
British Journal of Diabetes & Vascular Disease 2002;2:384-389.
ABSTRACT  

Dysmetabolic Syndrome: Multiple Risk Factors for Premature Adult Disease in an Adolescent Girl
Falkner et al.
Pediatrics 2002;110:e14-14.
ABSTRACT | FULL TEXT  

Ramipril and Risk of Diabetes
Potyk et al.
JAMA 2002;287:186-187.
FULL TEXT  

Can ACE Inhibitors Prevent Diabetes?
Journal Watch Cardiology 2001;2001:1-1.
FULL TEXT